These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34359801)

  • 1. Irreversible Electroporation and Nivolumab Combined with Intratumoral Administration of a Toll-Like Receptor Ligand, as a Means of In Vivo Vaccination for Metastatic Pancreatic Ductal Adenocarcinoma (PANFIRE-III). A Phase-I Study Protocol.
    Geboers B; Timmer FEF; Ruarus AH; Pouw JEE; Schouten EAC; Bakker J; Puijk RS; Nieuwenhuizen S; Dijkstra M; van den Tol MP; de Vries JJJ; Oprea-Lager DE; Menke-van der Houven van Oordt CW; van der Vliet HJ; Wilmink JW; Scheffer HJ; de Gruijl TD; Meijerink MR; On Behalf Of The Dutch Pancreatic Cancer Group
    Cancers (Basel); 2021 Aug; 13(15):. PubMed ID: 34359801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible Electroporation Combined with Checkpoint Blockade and TLR7 Stimulation Induces Antitumor Immunity in a Murine Pancreatic Cancer Model.
    Narayanan JSS; Ray P; Hayashi T; Whisenant TC; Vicente D; Carson DA; Miller AM; Schoenberger SP; White RR
    Cancer Immunol Res; 2019 Oct; 7(10):1714-1726. PubMed ID: 31409607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b trial of concurrent immunotherapy and irreversible electroporation in the treatment of locally advanced pancreatic adenocarcinoma.
    O'Neill C; Hayat T; Hamm J; Healey M; Zheng Q; Li Y; Martin RCG
    Surgery; 2020 Oct; 168(4):610-616. PubMed ID: 32631655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colorectal liver metastatic disease: efficacy of irreversible electroporation--a single-arm phase II clinical trial (COLDFIRE-2 trial).
    Scheffer HJ; Vroomen LG; Nielsen K; van Tilborg AA; Comans EF; van Kuijk C; van der Meijs BB; van den Bergh J; van den Tol PM; Meijerink MR
    BMC Cancer; 2015 Oct; 15():772. PubMed ID: 26497813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Percutaneous Irreversible Electroporation in Locally Advanced and Recurrent Pancreatic Cancer (PANFIRE-2): A Multicenter, Prospective, Single-Arm, Phase II Study.
    Ruarus AH; Vroomen LGPH; Geboers B; van Veldhuisen E; Puijk RS; Nieuwenhuizen S; Besselink MG; Zonderhuis BM; Kazemier G; de Gruijl TD; van Lienden KP; de Vries JJJ; Scheffer HJ; Meijerink MR
    Radiology; 2020 Jan; 294(1):212-220. PubMed ID: 31687922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of pancreatic cancer with irreversible electroporation and intratumoral CD40 antibody stimulates systemic immune responses that inhibit liver metastasis in an orthotopic model.
    Shankara Narayanan JS; Hayashi T; Erdem S; McArdle S; Tiriac H; Ray P; Pu M; Mikulski Z; Miller A; Messer K; Carson D; Schoenberger S; White RR
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36634919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ablation of Locally Advanced Pancreatic Cancer with Percutaneous Irreversible Electroporation: Results of the Phase I/II PANFIRE Study.
    Scheffer HJ; Vroomen LG; de Jong MC; Melenhorst MC; Zonderhuis BM; Daams F; Vogel JA; Besselink MG; van Kuijk C; Witvliet J; de van der Schueren MA; de Gruijl TD; Stam AG; van den Tol PM; van Delft F; Kazemier G; Meijerink MR
    Radiology; 2017 Feb; 282(2):585-597. PubMed ID: 27604035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irreversible electroporation ablation overcomes tumor-associated immunosuppression to improve the efficacy of DC vaccination in a mice model of pancreatic cancer.
    Yang J; Eresen A; Shangguan J; Ma Q; Yaghmai V; Zhang Z
    Oncoimmunology; 2021 Feb; 10(1):1875638. PubMed ID: 33643692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors.
    Babikr F; Wan J; Xu A; Wu Z; Ahmed S; Freywald A; Chibbar R; Wu Y; Moser M; Groot G; Zhang W; Zhang B; Xiang J
    Cell Mol Immunol; 2021 Dec; 18(12):2632-2647. PubMed ID: 34782757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploration of Novel Pathways Underlying Irreversible Electroporation Induced Anti-Tumor Immunity in Pancreatic Cancer.
    Imran KM; Nagai-Singer MA; Brock RM; Alinezhadbalalami N; Davalos RV; Allen IC
    Front Oncol; 2022; 12():853779. PubMed ID: 35372046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multicenter randomized controlled trial and registry study to assess the safety and efficacy of the NanoKnife® system for the ablation of stage 3 pancreatic adenocarcinoma: overview of study protocols.
    Narayanan G; Bilimoria MM; Hosein PJ; Su Z; Mortimer KM; Martin RCG
    BMC Cancer; 2021 Jul; 21(1):785. PubMed ID: 34233640
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation.
    Scheffer HJ; Stam AGM; Geboers B; Vroomen LGPH; Ruarus A; de Bruijn B; van den Tol MP; Kazemier G; Meijerink MR; de Gruijl TD
    Oncoimmunology; 2019; 8(11):1652532. PubMed ID: 31646081
    [No Abstract]   [Full Text] [Related]  

  • 13. Irreversible electroporation augments β-glucan induced trained innate immunity for the treatment of pancreatic ductal adenocarcinoma.
    Woeste MR; Shrestha R; Geller AE; Li S; Montoya-Durango D; Ding C; Hu X; Li H; Puckett A; Mitchell RA; Hayat T; Tan M; Li Y; McMasters KM; Martin RCG; Yan J
    J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
    Hong Y; Rice J; Sharma D; Martin RCG
    Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer.
    Carbone C; Piro G; Agostini A; Delfino P; De Sanctis F; Nasca V; Spallotta F; Sette C; Martini M; Ugel S; Corbo V; Cappello P; Bria E; Scarpa A; Tortora G
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
    Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
    J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
    Timmer FEF; Geboers B; Ruarus AH; Schouten EAC; Nieuwenhuizen S; Puijk RS; de Vries JJJ; Meijerink MR; Scheffer HJ
    Tech Vasc Interv Radiol; 2020 Jun; 23(2):100675. PubMed ID: 32591191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irreversible electroporation promotes a pro-inflammatory tumor microenvironment and anti-tumor immunity in a mouse pancreatic cancer model.
    Imran KM; Brock RM; Beitel-White N; Powar M; Orr K; Aycock KN; Alinezhadbalalami N; Salameh ZS; Eversole P; Tintera B; Markov Madanick J; Hendricks-Wenger A; Coutermarsh-Ott S; Davalos RV; Allen IC
    Front Immunol; 2024; 15():1352821. PubMed ID: 38711517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MR and CT imaging characteristics and ablation zone volumetry of locally advanced pancreatic cancer treated with irreversible electroporation.
    Vroomen LGPH; Scheffer HJ; Melenhorst MCAM; de Jong MC; van den Bergh JE; van Kuijk C; van Delft F; Kazemier G; Meijerink MR
    Eur Radiol; 2017 Jun; 27(6):2521-2531. PubMed ID: 27659702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Needle-guided ablation of locally advanced pancreatic cancer: cytoreduction or immunomodulation by in vivo vaccination?
    Geboers B; Ruarus AH; Nieuwenhuizen S; Puijk RS; Scheffer HJ; de Gruijl TD; Meijerink MR
    Chin Clin Oncol; 2019 Dec; 8(6):61. PubMed ID: 31865711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.